Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
25%(1 trials)

Phase Distribution

Ph phase_1
2
33%
Ph phase_2
2
33%
Ph phase_3
1
17%

Phase Distribution

2

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(4)
Other(2)

Detailed Status

Completed4
unknown2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (40.0%)
Phase 22 (40.0%)
Phase 31 (20.0%)

Trials by Status

unknown233%
completed467%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_2

Convalescent Plasma to Limit SARS-CoV-2 Associated Complications

NCT04373460
completedphase_2

Convalescent Plasma for Treatment of COVID-19

NCT04649879
completedphase_1

Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19)

NCT04390178
completedphase_1

Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study

NCT04384497
unknown

SARSCoV2 (COVID-19) Convalescent Plasma (CP) Expanded Access Protocol (EAP)

NCT04374370
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04373460Phase 2

Convalescent Plasma to Limit SARS-CoV-2 Associated Complications

Completed
NCT04649879Phase 2

Convalescent Plasma for Treatment of COVID-19

Completed
NCT04390178Phase 1

Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19)

Completed
NCT04384497Phase 1

Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study

Completed
NCT04374370

SARSCoV2 (COVID-19) Convalescent Plasma (CP) Expanded Access Protocol (EAP)

Unknown
NCT04836260Phase 3

Preemptive Use of Convalescent Plasma for High-risk Patients With COVID-19

Unknown

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6